Risk of confirmed disability progression (FAS)
| Outcome | Treatment | Patients without progression (95% CI)† | Between-treatment comparison* | ||
| Risk reduction (%) | HR (95% CI) | P value | |||
| 3M-CDP | Fingolimod n/N=5/107 | 95.2% (91.1 to 99.3) | 77.2 | 0.23 (0.08 to 0.66) | 0.007 |
| INF β-1a n/N=15/107 | 84.7% (77.5 to 91.9) | ||||
| Sustained 3M-CDP‡ | Fingolimod n/N=2/107 | 98.1% (95.5 to 100.0) | 87.4 | 0.13 (0.02 to 0.64) | 0.013 |
| INF β-1a n/N=9/107 | 90.6% (84.7 to 96.5) | ||||
| 6M-CDP | Fingolimod n/N=3/107 | 97.1% (93.9 to 100.0) | 80.2% | 0.20 (0.04 to 0.93) | 0.040 |
| INF β-1a n/N=7/107 | 93.0% (88.0 to 98.0) | ||||
*Performed on time to event using a Cox regression model adjusted as described in methodology.
†Estimated at month 24 from Kaplan-Meier analysis.
‡3M-CDP sustained until last observation.
FAS, full analysis set; IFN, interferon; 3M-CDP, 3 month confirmed disability progression; 6M-CDP, 6 month confirmed disability progression; N, total number of patients included in the analysis; n, total number of events included in the analysis.